Annovis Bio Inc
$ 3.60
-1.64%
26 Dec - close price
- Market Cap 59,803,000 USD
- Current Price $ 3.60
- High / Low $ 3.72 / 3.49
- Stock P/E N/A
- Book Value 0.66
- EPS -2.10
- Next Earning Report 2026-03-23
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.12 %
- ROE -3.65 %
- 52 Week High 5.60
- 52 Week Low 1.11
About
Annovis Bio, Inc. is a clinical-stage biotechnology company headquartered in Berwyn, Pennsylvania, dedicated to the development of transformative therapies for neurodegenerative diseases, primarily targeting Alzheimer's and Parkinson's. Utilizing its proprietary platform, the company focuses on addressing the root causes of neurodegeneration to restore neurological function and meet significant unmet medical needs associated with cognitive decline in aging populations. With an advancing pipeline supported by rigorous clinical trials, Annovis Bio presents a significant investment opportunity for institutional investors seeking innovative solutions within the neurology sector that have the potential to enhance patient outcomes.
Analyst Target Price
$13.75
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-12 | 2025-05-08 | 2025-03-27 | 2024-11-06 | 2024-08-14 | 2024-05-10 | 2024-03-29 | 2023-11-08 | 2023-08-14 | 2023-05-10 | 2023-03-01 |
| Reported EPS | -0.37 | -0.32 | -0.32 | -0.43 | -0.97 | -0.32 | -0.72 | -2.24 | -1.63 | -1.07 | -1.19 | -1.05 |
| Estimated EPS | -0.305 | -0.4031 | -0.8 | -0.2 | -0.53 | -0.63 | -0.8 | -1.3 | -1.09 | -1.14 | -0.33 | -1.05 |
| Surprise | -0.065 | 0.0831 | 0.48 | -0.23 | -0.44 | 0.31 | 0.08 | -0.94 | -0.54 | 0.07 | -0.86 | 0 |
| Surprise Percentage | -21.3115% | 20.6152% | 60% | -115% | -83.0189% | 49.2063% | 10% | -72.3077% | -49.5413% | 6.1404% | -260.6061% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-23 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.31 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ANVS
2025-12-24 20:09:29
Annovis Bio, Inc. (NYSE: ANVS) announced a new 36-month open-label extension study for its experimental Parkinson’s drug, buntanetap, enrolling up to 500 patients starting January 2026. This study will assess long-term safety and effectiveness, including patients previously in Annovis trials and those undergoing deep brain stimulation. The goal is to understand buntanetap's sustained benefits on motor and cognitive symptoms and its interaction with surgical interventions.
2025-12-23 20:08:50
Annovis Bio, Inc. (NYSE: ANVS) announced it will host an investor webinar on Wednesday, January 28, 2026, at 4:30 p.m. Eastern, to provide a corporate update as its neurodegeneration pipeline enters a "milestone-rich period." The webinar will feature President and CEO Maria Maccecchini discussing company progress, clinical study updates, and strategic direction, followed by a live Q&A session. The company focuses on developing therapies for Alzheimer's and Parkinson's diseases, aiming to slow or halt neurodegeneration.
2025-12-19 21:09:17
Annovis Bio, Inc. (NYSE:ANVS) announced it will initiate an Open-Label Extension study in January 2026 to assess the long-term safety and efficacy of its drug buntanetap for Parkinson's disease. The 36-month study will enroll 500 patients across multiple U.S. sites, including participants from previous trials and those receiving deep brain stimulation. This study aims to fulfill FDA patient exposure requirements and represents a significant step towards a potential New Drug Application submission.
2025-12-19 20:08:51
Annovis Bio (NYSE: ANVS) announced it will host a corporate update webinar on January 28, 2026, at 4:30 p.m. ET, featuring President and CEO Maria Maccecchini, Ph.D. The webinar will cover recent progress, ongoing late-stage clinical programs for Alzheimer's and Parkinson's disease, strategic direction, and early 2026 milestones, followed by a live Q&A session. This announcement follows several positive price reactions to recent clinical and regulatory milestones.
2025-12-19 09:08:57
Annovis Bio, Inc. is initiating a 36-month open-label extension study to assess Buntanetap's long-term effects on Parkinson's disease patients, including those previously on other studies and deep brain stimulation patients. The study aims to gather crucial data on safety, efficacy, and disease modification, supporting future regulatory submissions. This initiative follows positive Phase 3 results for Buntanetap in early Parkinson's disease.
2025-12-18 21:08:57
Annovis Bio, Inc. announced an Open-Label Extension (OLE) study for its drug buntanetap in Parkinson's disease patients, starting January 2026. This 36-month study aims to enroll 500 participants, including former clinical trial participants and those undergoing deep brain stimulation, to assess long-term safety and efficacy. The study is crucial for gathering biomarker data and fulfilling patient exposure requirements for a future New Drug Application (NDA) submission to the FDA.
